• Maamoun Basheer, Elias Saad, Faris Milhem, Dmitry Budman, and Nimer Assy.
• Department of Internal Medicine, Galilee Medical Center, Nahariya, Israel, Biotechnology and Radiology Laboratory, Hadassah Medical Organization and Faculty of Medicine.
• Isr Med Assoc J. 2022 Nov 1; 24 (11): 695696695-696.

AbstractCoronavirus disease 2019 (COVID-19) affects different people in different ways. Most infected people develop mild to moderate illness and recover without hospitalization. This case report presents a patient who had difficulty eradicating the corona virus due to being treated with rituximab, which depletes B lymphocytes and therefore disables the production of neutralizing antibodies. The regen-COV-2 antibody cocktail consists of two monoclonal antibodies, casirivimab and imdevimab. This cocktail successfully helped the patient's immune system eradicate the virus without auto specific severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody production. In vitro studies confirm that eradication of the intact the virus. This case report emphases the importance of providing external antiviral antibodies regularly, like the regen-COV-2 antibody cocktail, as post- and even pre- SARS-CoV-2 infection prophylaxis in patients treated with rituximab.

6 keywords...

hide…